Biopharmaceutical CMO and CRO Market Size is projected to reach USD 51.36 billion by 2030, growing at a CAGR of 6.68%: Straits Research

The Global Biopharmaceutical CMO and CRO Market was valued at USD 28.70 billion in 2021 and is predicted to reach at USD 51.36 billion by 2030, increasing at a CAGR of 6.68% from 2022 to 2030. In 2021, the revenue share held by North America was the highest, at about 35 percent of total revenue.

| Source: Straits Research Straits Research

New York, United States, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Biopharmaceutical CMOs and CROs are crucial to industry success. Biopharmaceuticals affect CMOs and CROs. Demand for biopharmaceutical treatments has fueled the industry's growth. Globally, biopharmaceuticals make up over 20% of the pharmaceutical industry.

A contract manufacturing organization (CMO) contracts with other pharmaceutical companies to produce new medications. Contract research organizations (CROs) supply pharmaceutical, biotechnology, and medical device firms with research services. Biopharmaceutical development, biological assay design and commercialization, preclinical and clinical testing.

COVID-19 boosted 2020 cases dramatically. Biopharmaceutical industry leaders have increased output and efficiency investments to compete. Biopharmaceutical businesses are outsourcing resource- and capital-intensive phases, and often the entire biomanufacturing chain, increasing the need for contract services.

COVID-19 has disturbed the pharmaceutical supply chain. Biopharmaceutical CMOs and CROs have responded well to the outbreak due to supply chain bottlenecks. Pandemics would help CMOs and CROs in the Western Hemisphere.


Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/biopharmaceutical-cmo-and-cro-market/request-sample


Global Biopharmaceutical CMO and CRO Market: DRIVERS 

  • Strong Biologics Pipeline Drives Need for Biopharmaceutical CMO and CRO Services

This business will grow as pharmaceutical and biotech corporations spend more on contractual development and production services. Smaller CMOs foresee faster growth than larger CMOs during the projection period. The significant growth rate is due to the increasing number of biologics pipelines anticipated for release throughout the projection period. Biopharmaceutical pipeline growth will boost outsourcing.

The FDA authorized 64 new molecules and biologics in 2018. Mergers and acquisitions are likely to expand in the biopharmaceutical CMO & CRO market, boosting revenue.

  • Single-Use Systems and New Bioprocessing Technologies

Recent years have seen many biopharmaceutical mergers. Biopharmaceutical contract manufacturing and services aspire to grow with these mergers.

New medicines, bioprocessing techniques, and a bio/pharmaceutical goods shift are likely to put pressure on contract bio manufacturers. Alternative business models are being adopted to fulfil the needs of stakeholders and customers. Given these factors, the biopharmaceutical CMO and CRO market is likely to grow rapidly.

Single-use systems will increase biopharmaceutical CMO and CRO manufacturing capacity. This is predicted to boost worldwide biopharmaceutical CMO and CRO market growth during the forecast period.


Global Biopharmaceutical CMO and CRO Market Report Scope

Report MetricDetails
  Market SizeUSD 51.36 Billion by 2030
  CAGR6.68% (2020-2030)
  Historical Data2019-2020
  Base Year2021
  Forecast Period2022-2030
  Forecast UnitsValue (USD Billion)
  Report CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments CoveredBy Source, Service, Product, and Region
  Geographies CoveredNorth America, Europe, Asia-Pacific, LAME and Rest of the World
  Key Companies Profiled/VendorsInno Biologics Sdn Bhd | Rentschler Biopharma SE | ProBioGen AG | Fujifilm Diosynth Biotechnologies U.S.A., Inc. | Toyobo Co., Ltd. | Lonza Group AG | Patheon | CMC Biologics | Biomeva GmbH | Samsung Biologics | AbbVie Inc. | WuXi Biologics | JRS Pharma | Boehringer Ingelheim GmbH | Binex Co., Ltd.
  Key Market OpportunitiesInitiatives To Develop Innovative Growth Opportunities
  Key Market DriversDemand For Biopharmaceutical CMO And CRO Services to Rising Due to Strong Biologics Pipeline

Buy Now Full Report @ https://straitsresearch.com/buy-now/biopharmaceutical-cmo-and-cro-market 


Global Biopharmaceutical CMO and CRO Market: KEY FUTURE OPPORTUNITIES

  • Growth Initiatives for Future Opportunities

Biopharmaceutical CMOs and CROs are implementing innovative growth prospects. Expanding R&D effort and investment is key to market growth. Regional expansions, new product development, industry collaboration, distribution network expansion, and mergers & acquisitions are other growth techniques to gain a competitive advantage in the global market.

Lonza and Moderna will share COVID-19 vaccine production for ten years. These advances helped catch up clinical trial delays in 2020's first half. Future growth is expected in the contract manufacturing business. In view of biopharmaceutical businesses' diminishing R&D efficiency and escalating development expenses, CMOs & CROs have appealing prospects to expedite their business processes.


Regional Overview of Biopharmaceutical CMO and CRO Market

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa make up the biopharmaceutical CMO and CRO market.

North America held 35% of overall revenue in 2021. This is because many service providers are nearby. CMOs produce a large portion of US-approved products. Emergence of small and midsized biopharmaceutical firms (SMEs) without means to build well-equipped facilities is challenging. CMOs and SMEs in the US have become more dependent on one other, making the US market the most dominating globally.

Asia Pacific is expected to increase rapidly during the projected period. Lower labor and operations expenses in Asia are driving the surge in outsourcing. This is why Asian countries outsource more. India's large-molecule manufacturing is expected to boost its economy. The lack of worldwide biosimilar regulatory standardization has propelled the Indian market. In 2016, India approved 50 biosimilars, compared to 24 in Europe and 5 in the US.


Key Highlights

  • The Global Biopharmaceutical CMO and CRO Market Size was valued at USD 28.70 billion in 2021. The market is projected to grow from USD 30.62 billion in 2022 to USD 51.36 billion by 2030, increasing at a CAGR of 6.68% during the forecast period 2022 to 2030.
  • By Source, the Global Biopharmaceutical CMO and CRO Market is segmented into Mammalian and Non-mammalian. Due to a dearth of internal knowledge within the sector, the mammalian category held the biggest market share in 2021
  • By Service, the Global Biopharmaceutical CMO and CRO Market is segmented into Contract Manufacturing and Contract Research. The contract research category is anticipated to display the highest growth over the course of the projection year.
  • By Product, the Global Biopharmaceutical CMO and CRO Market is segmented into Biologics and Biosimilars. The biologics sector was the dominant player in the market in 2021.
  • By Region or Geography, the Global Biopharmaceutical CMO and CRO Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America had dominated the market.


Get a Free Sample Copy of this report @ https://straitsresearch.com/report/biopharmaceutical-cmo-and-cro-market/request-sample


Major Players in Global Biopharmaceutical CMO and CRO Market 

List of major competitor companies in the Biopharmaceutical CMO and CRO Market across the globe are:

  1. Inno Biologics Sdn Bhd
  2. Rentschler Biopharma SE
  3. ProBioGen AG
  4. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  5. Toyobo Co., Ltd.
  6. Lonza Group AG
  7. Patheon
  8. CMC Biologics
  9. Biomeva GmbH
  10. Samsung Biologics
  11. AbbVie Inc.
  12. WuXi Biologics
  13. JRS Pharma
  14. Boehringer Ingelheim GmbH
  15. Binex Co., Ltd.


Global Biopharmaceutical CMO and CRO Market: Segmentation 

BY SOURCE

  • Mammalian
  • Non-mammalian

BY SERVICE

  • Contract Manufacturing
  • Contract Research

BY PRODUCT

  • Biologics
  • Biosimilars

BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific (APAC)
  • Latin America
  • Middle East and Africa (MEA)


TABLE OF CONTENT

  1. Introduction
    1. Biopharmaceutical CMO and CRO Market Definition
    2. Biopharmaceutical CMO and CRO Market Scope
  2. Research Methodology
    1. Primary Research
    2. Research Methodology
    3. Assumptions & Exclusions
    4. Secondary Data Sources
  3. Market Overview
    1. Report Segmentation & Scope
    2. Value Chain Analysis: Biopharmaceutical CMO and CRO Market
    3. Key Market Trends
      1. Drivers
      2. Restraints
      3. Opportunities
    4. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
    5. Biopharmaceutical CMO and CRO Market Share Analysis
  4. Source Overview
    1. Introduction
      1. Market Size & Forecast
    2. Mammalian
      1. Market Size & Forecast
    3. Non-mammalian
      1. Market Size & Forecast
  5. Services Overview
    1. Introduction
      1. Market Size & Forecast
    2. Contract Manufacturing
      1. Market Size & Forecast
    3. Contract Research
      1. Market Size & Forecast
  6. Regional Overview
    1. Introduction
      1. Market Size & Forecast
    2. America
      1. North America
      2. U.S.
        1. By Source
        2. By Services
      3. Canada
        1. By Source
        2. By Services
      4. Mexico
        1. By Source
        2. By Services
      5. Latin America
        1. By Source
        2. By Services
    3. Europe
      1. Market Size & Forecast
      2. Germany
        1. By Source
        2. By Services
      3. France
        1. By Source
        2. By Services
      4. U.K.
        1. By Source
        2. By Services
      5. Italy
        1. By Source
        2. By Services
      6. Spain
        1. By Source
        2. By Services
      7. Rest of Europe
        1. By Source
        2. By Services
    4. Asia Pacific
      1. Market Size & Forecast
      2. Japan
        1. By Source
        2. By Services
      3. China
        1. By Source
        2. By Services
      4. Australia
        1. By Source
        2. By Services
      5. India
        1. By Source
        2. By Services
      6. South Korea
        1. By Source
        2. By Services
      7. Rest of Asia-Pacific
        1. By Source
        2. By Services
    5. Middle East & Africa
      1. Market Size & Forecast
      2. Saudi Arabia
        1. By Source
        2. By Services
      3. South Africa
        1. By Source
        2. By Services
      4. Kuwait
        1. By Source
        2. By Services
      5. Rest of Middle East & Africa
        1. By Source
        2. By Services
  7. Company Profile
    1. Toyobo Co Ltd
      1. Company Overview
      2. Financial Performance
      3. Recent Developments
      4. Product Portfolio
    2. Lonza Group AG
      1. Company Overview
      2. Financial Performance
      3. Recent Developments
      4. Product Portfolio
    3. Patheon
      1. Company Overview
      2. Financial Performance
      3. Recent Developments
      4. Product Portfolio
  8. Conclusion & Recommendation
  9. Acronyms & Abbreviations


Table of Content and Figure @ https://straitsresearch.com/report/biopharmaceutical-cmo-and-cro-market/toc 


Recent Developments

  • May 2022 - Germany's Boehringer Ingelheim (BI) has announced that it has acquired approval from the Central Drugs Standard Control Organization (CDSCO) to market its medicine Jardiance (empagliflozin) in India, for the whole spectrum of heart failure disorders regardless of ejection fraction.
  • January 2022 - An agreement to acquire a cell treatment manufacturing facility from Atara Biotherapeutics, Inc. for USD 100 million has been announced by Fujifilm Corporation. Clinical and commercial cell treatments, such as allogeneic T-cells and CAR T immunotherapies, can be produced in this facility, which is conveniently located in Thousand Oaks, California.


News Media
Pharmaceutical Companies Focusing on Brand Protection to Drive Track and Trace Solutions Market Growth
Biopharmaceutical Logistics Market to Reach USD 131,554.1 million by 2026 at a CAGR of 6.2%
E-Clinical Software Solutions to Emerge as The Future of Clinical Trials
North America Dominates the ePharmacy Market


Have a Look at the Related Research Report
E-Clinical Solution Software Market Share: Information by Product (Clinical Analytical Platform, CTMS), Delivery Mode (Licensed Enterprise), End User (CROs) and Regional Outlook—Forecast Till 2026
Machine-to-Machine (M2M) Healthcare Market: Information by Technology (Wired, Wireless) Application (Remote Health Monitoring, Clinical Monitoring, Fitness) and Region-Forecast Till 2026 
Esoteric Testing Market Report: Information by Type (Infectious Disease, Endocrinology), Technology (Chemiluminescence Immunoassay), End-User (Hospital Laboratories), and Region — Forecast till 2029 
Clinical Trial Management System Market Growth: information by Type (Enterprise & Site), Component (Software & Services), Delivery Mode (Cloud, On-premises & Web-based)-Forecast Till 2026
Digital PCR Market Analysis: Information by Technology (Droplet Digital PCR, Chip-based Digital PCR), Application (Research, Clinical Diagnostics), and Region — Forecast till 2030


About Straits Research Pvt. Ltd.

StraitsResearch is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)             

+44 208 068 9665 (the U.K.)

Email: sales@straitsresearch.com

Follow Us: LinkedIn | Facebook | Instagram | Twitter


Tags

Biopharmaceutical CMO and CRO CMO And CRO Market pharmaceutical biotech biologics preclinical clinical testing biomanufacturing

Related Links